Pfizer and Protalix BioTherapeutics have obtained approval from the Brazilian National Health Surveillance Agency for Uplyso (alfataliglicerase) as type I Gaucher disease therapy. Uplyso, referred to as Elelyso (taliglucerase alfa) ...
Tags: Pfizer, Protalix, Protalix BioTherapeutics
Israel-based Protalix BioTherapeutics has signed an agreement with Pfizer to continue managing the development activities of Gaucher disease drug Elelyso. According to the clinical development agreement, Protalix will continue to manage ...
Tags: Protalix, Pfizer, Gaucher disease drug